mRNA-1273.617.2

BIOLOGICAL2 trials

Sponsors

ModernaTX, Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19SARS-CoV-2

Phase 2

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

CompletedNCT04927065

ModernaTX, Inc.SARS-CoV-2

Start: 2021-05-28End: 2023-11-17Updated: 2025-02-28

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

CompletedNCT05289037

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2022-03-30End: 2023-11-27Updated: 2025-10-17

Related Papers

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

Vaccine2025-09-09

P-102. Six-Month Safety, Durability, and Cross-Neutralization of the SARS-CoV-2 XBB.1.5-Containing Vaccine

Open Forum Infectious Diseases2025-01-29

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

2025-01-177 citations

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Nature Medicine2023-08-3168 citations

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.

2023-08-2839 citations

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

2023-08-2320 citations

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.

2022-10-06121 citations

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

New England Journal of Medicine2022-09-16635 citations